New insider activity at Idexx Laboratories ( (IDXX) ) has taken place on August 13, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EVP Nimrata Hunt recently sold 1,200 shares of Idexx Laboratories stock, amounting to a total transaction value of $787,836.
Recent Updates on IDXX stock
Idexx Laboratories reported strong financial results for Q2 2025, with an 11% revenue growth and a 49% increase in earnings per share, driven by international performance and record instrument placements. The company’s innovation-driven strategy, particularly with IDEXX InVue Dx(TM) and IDEXX Cancer Dx(TM), contributed to this growth by enhancing diagnostic capabilities and customer loyalty. Despite challenges in the U.S. market, such as declining clinical visits and rapid assay revenue, Idexx remains optimistic, raising its full-year revenue and EPS guidance. Analysts have adjusted price targets upwards, reflecting confidence in Idexx’s strategic focus on innovation and international expansion amid macroeconomic pressures.
Spark’s Take on IDXX Stock
According to Spark, TipRanks’ AI Analyst, IDXX is a Outperform.
Idexx Laboratories demonstrates strong financial performance and positive earnings call sentiment, driving a high overall score. Technical indicators support a bullish outlook, although the high P/E ratio suggests the stock is expensive. The company’s strategic focus on international markets and innovation positions it well for future growth.
To see Spark’s full report on IDXX stock, click here.
More about Idexx Laboratories
YTD Price Performance: 59.54%
Average Trading Volume: 603,771
Technical Sentiment Signal: Buy
Current Market Cap: $52.18B